11 Jun 2019

Melvyn’s story

In 2012 Melvyn, a bone marrow transplant patient, suffering from an aggressive form of graft-versus-host-disease was given pioneering, life-saving treatment, Mesenchymal Stem Cell Therapy, at The Catherine Lewis Centre.

“I was first diagnosed with leukaemia in July 1998 after complaining of fatigue to my local GP,” says Melvyn.

“I didn’t know what the disease was at the time but my wife Pauline took the news very badly as she understood what the outcome could be.

“I wanted to see my children graduate – my daughter was 13 and my son 15 – so I was determined to fight it and stay positive. It was a huge shock for my family.”

Melvyn successfully underwent a stem cell transplant just 10 weeks later, and although he responded well initially he started to experience a serious complication called graft-versus-host-disease (GvHD), where the newly transplanted cells attack the recipient’s body.

“I remember reaching out to turn the bedside lamp off and noticing for the first time hard lumps on my arms. By the time I went to clinic, it had spread all over my body from my neck to my ankles and my skin had become so thick that I found it hard to move.

“I saw the rheumatologist and started a new steroid drug regime, it worked well for around two years, but the risk of infection and relapse were so high that I stopped taking them.

“After a couple of years GvHD deteriorated; but thankfully, because of research funded by Leukaemia UK, I was given the opportunity to trial a new treatment called Mesenchymal Stem Cell Therapy, which has significantly improved my life.”

Professor Francesco Dazzi

“Leukaemia UK has enabled us to initiate this treatment and gather preliminary evidence with some extraordinary results. In Melvyn’s case, we isolated cells taken from his daughter, prepared them here at The Catherine Lewis Centre and, when they were ready, we infused them.

“We have seen a 50% improvement in Melvyn’s condition and I am thrilled that we have been able to improve both his outlook and quality of life.”

Related posts

1 in 4 leukaemia patients in England experiences an avoidable delay in diagnosis

18 September 2025

1 in 4 leukaemia patients in England experiences an avoidable delay in diagnosis

A first of its kind study, commissioned by Leukaemia UK, has revealed that a quarter (26%) of leukaemia patients in England experience avoidable delays in their diagnosis, resulting in a…

Three leading charities collaborate to fight childhood cancers

2 October 2023

Three leading charities collaborate to fight childhood cancers

New Partnership we3can to fund research into three most common childhood cancers Today (2nd October 2023), three leading cancer charities have launched a new collaboration in order to improve the…

Leukaemia UK announces John Goldman Fellows for 2022

8 November 2022

Leukaemia UK announces John Goldman Fellows for 2022

Leukaemia UK has awarded their prestigious John Goldman Fellow research grants to four outstanding early-career researchers seeking to advance our understanding of and ability to treat blood cancer. Leukaemia UK…

A new clinical trial announced

21 May 2020

A new clinical trial announced

A study into the impact of severe covid-19 infection on patients who receive stem cell transplants for blood cancers and blood disorders.